Astellas Pharma reveals findings from Phase 3 GATHER2 trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Study Results: Astellas Pharma reported positive results from the open-label extension trial of the Phase 3 GATHER2 study, showing that monthly treatment with IZERVAY significantly reduced geographic atrophy (GA) lesion growth in patients with age-related macular degeneration (AMD) for up to 3.5 years.
Safety and Efficacy: The treatment was well tolerated with no reported cases of retinal vasculitis, and earlier intervention led to greater protection of retinal tissue, with a reduction in GA growth of 37-40.5% compared to projected sham treatments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
